 BOULDER, Colo.--BUSINESS WIRE--- BDSX patientsfirst--Biodesix, Inc. Nasdaq: BDSX, a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test cPassTM Neutralization Test Kit, GenScript Inc.. The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor binding domain RBD of the severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 virus and is the first and o 